CorreGene

Focus: CorreGene is an early-stage Chinese biotech company focused on TCR cell and antibody therapies for oncology, founded in 2022. The company is pre-revenue with a nascent pipeline of three Phase 1 programs.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About CorreGene

AI assessmentNot Hiring

No open roles listed right now. Follow CorreGene to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Fludarabine + Cyclophosphamide

Cervical Cancer

Phase 1

Clinical Trials (1)

NCT05122221CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers

Phase 1

Help build intelligence for CorreGene

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a founder-stage company entering the high-value TCR-T cell therapy space with differentiated KRAS-targeting approach
Exposure to cutting-edge cell therapy and oncology development in a growth market with significant unmet need
Potential for significant equity upside and rapid career progression given early-stage company structure

Watch Out For

Company has zero active job openings and minimal public hiring signals, suggesting limited near-term expansion or potential hiring freeze
Very early stage (founded 2022, Phase 1 only) with undisclosed funding and financial position creates uncertainty around cash runway and company viability
Based in Beijing with no disclosed H1B sponsorship capability, creating visa/relocation barriers for non-China-based professionals

Generated by Claude from CorreGene's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

CRTE7A2-01 TCR-T cell therapy

Cervical Cancer

Phase 1

Clinical Trials (1)

NCT06358053CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers

Phase 1

KRAS-specific Autologous TCR-T cell injection

Colorectal

Phase 1

Clinical Trials (1)

NCT06767046KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors

Phase 1